TDAC · Translational Development Acquisition Corp.
$10.85
+0.01 (+0.05%)
At close · Aug 5
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company’s assessment of going concern considerations in accordance with ASC 205-40, “Presentation of Financial Statements-Going Concern,” management has determined that the liquidity issues and mandatory liquidation and subsequent dissolution, should the Company be unable to complete a Business Combination by the end of the Completion Window, raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 24, 2026. The Company’s plan to deal with the uncertainty is to complete a Business Combination prior to June 24, 2026 and to receive working capital from its Sponsor. There is no assurance that the Company’s plans to consummate a Business Combination or to receive working capital from the Sponsor will be successful.”View the 10-Q filed May 15, 2026
Market Cap
$237.59M
Shares
21.91M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.85
Open$10.84
Day$10.84–10.89
52W$10.32–10.95
Avg vol 30d27K
Short int5K · 0.0% float · 1.0d
Short vol69%
DataFeb 2025–Aug 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+1%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
83%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+3%
trailing
YTD return
+3%
this year
Relative strength
−8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
4 of 48 funds reported for Jun 30 · net -106.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.02% of float · ▲ +64.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
48 holders — near 1-yr high, broad support
Squeeze score
40
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
2%
annualized · 1-yr
Max drawdown
−1%
past year
ATR
0.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
83%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow
Distributing
4 of 48 funds reported for Jun 30 · net -106.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.02% of float · ▲ +64.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
48 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $11 · 83%
52-wk high $11
vs 200-day avg +3%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TDAC
this stock
Translational Development Acquisition Corp.
|
$237.59M | +3.4% | — | — | 0.0% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | +0.0% | — | 100.2 | — |
|
NIMU
Non Invasive Monitoring Systems Inc /Fl/
|
$1.63B | +2943.5% | -73.9% | — | 0.0% |
|
CCXI
Churchill Capital Corp XI
|
$887.30M | — | — | — | 1.8% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$644.01M | +2.1% | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TDAC | +0.2% | +1.4% | +2.9% | +0.1% | +3.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -5.3% | -1.9% | -8.3% | -2.9% | -9.5% |